The predictions obtained through this model were compared against available retrospective clinical data from published trials with monoclonal antibodies blocking the PD-1/PD-L1 pathway for validation, thereby focusing on a quantitative relationship between tumor response and its underlying mechanisms. Here, CD274 is linked to neoplasm.